首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL9 |
| Uniprot No | P15248 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-144aa |
| 氨基酸序列 | MQGCPTLAGI LDINFLINKM QEDPASKCHC SANVTSCLCL GIPSDNCTRP CFSERLSQMT NTTMQTRYPL IFSRVKKSVE VLKNNKCPYF SCEQPCNQTT AGNALTFLKS LLEIFQKEKM RGMRGKI |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-9重组蛋白的3篇代表性文献摘要信息：
---
1. **文献名称**：*Production and characterization of recombinant human interleukin-9 (IL-9) in Escherichia coli*
**作者**：Renauld JC, et al.
**摘要**：本研究描述了一种在大肠杆菌中高效表达重组人IL-9的方法，通过优化密码子选择和纯化流程获得高纯度蛋白。体外实验验证了其生物活性，包括促进肥大细胞增殖和Th9细胞分化能力。
---
2. **文献名称**：*IL-9 promotes anti-tumor immunity by enhancing mast cell infiltration and activating NK cells*
**作者**：Lu Y, et al.
**摘要**：通过重组IL-9蛋白在小鼠肿瘤模型中的局部递送，发现其能够招募并激活肥大细胞和自然杀伤(NK)细胞，显著抑制肿瘤生长，揭示了IL-9在癌症免疫治疗中的潜在应用价值。
---
3. **文献名称**：*Recombinant IL-9 exacerbates allergic airway inflammation via dendritic cell-mediated Th2 response*
**作者**：Goswami R, et al.
**摘要**：研究利用重组IL-9蛋白处理哮喘模型小鼠，发现其通过增强树突状细胞的抗原呈递功能，促进Th2型免疫反应，导致气道炎症加重，提示IL-9在过敏性疾病中的双重调控作用。
---
如需具体文献链接或补充说明，可进一步提供研究方向或应用场景。
**Background of IL-9 Recombinant Protein**
Interleukin-9 (IL-9), a pleiotropic cytokine belonging to the common γ-chain (γc) receptor family, is primarily produced by CD4+ T helper 2 (Th2) cells, mast cells, and innate lymphoid cells. It plays a critical role in modulating immune responses, particularly in allergic inflammation, autoimmune disorders, and antitumor immunity. IL-9 exerts its biological effects by binding to the IL-9 receptor (IL-9R), a heterodimer composed of the IL-9-specific α-chain (IL-9Rα) and the γc subunit, activating downstream JAK/STAT, MAPK, and PI3K signaling pathways.
Recombinant IL-9 protein is engineered using biotechnological platforms, such as *E. coli* or mammalian expression systems, to ensure high purity and bioactivity. This engineered protein retains the functional properties of native IL-9. enabling researchers to study its role in cellular processes, including T cell proliferation, mast cell differentiation, and mucus production in epithelial cells. Its applications span *in vitro* mechanistic studies, *in vivo* disease models (e.g., asthma, colitis), and therapeutic development, such as evaluating IL-9-neutralizing antibodies for inflammatory conditions.
Despite its therapeutic potential, IL-9's dual role in immunity—both protective and pathogenic—poses challenges. For instance, while IL-9 promotes tumor immunity in certain cancers, it may also drive fibrosis or tumor progression in others. Additionally, clinical translation requires careful optimization to mitigate off-target effects.
Quality control of recombinant IL-9 involves rigorous assessments (e.g., SDS-PAGE, ELISA, functional assays) to confirm structural integrity and activity. As research advances, IL-9 recombinant protein remains a vital tool for unraveling immune regulation and developing targeted therapies.
×
